Streetbeat News

Regulatory

TAK

Takeda Pharmaceuticals (TAK) has received approval from the U.S. Food and Drug Administration (FDA) for a subcutaneous administration of ENTYVIO for maintenance therapy in adults with moderately to severely active ulcerative colitis. The new administration method is expected to be available in the U.S. by the end of October. Takeda does not expect this approval to materially impact its full year consolidated reported forecast for the year ending March 31, 2024.

Portfolio Pulse from Happy Mohamed

September 27, 2023 | 8:27 pm

SNT

Senstar Technologies Ltd. (NASDAQ:SNT), a provider of security products and solutions, plans to move its corporate domicile from Israel to Ontario, Canada. The majority of the company's employees and operating assets are in Canada. The redomiciliation, subject to shareholder approval, is expected to close in Q4 2023 and is not expected to materially impact day-to-day operations.

Portfolio Pulse from Happy Mohamed

September 27, 2023 | 8:23 pm

MSOS

Erica Rice, Co-Chair of Foley Hoag's Cannabis and Mergers & Acquisitions Practices, spoke at the Benzinga Cannabis Capital Conference. She emphasized the importance of obtaining a license and considering state requirements upfront in the cannabis industry.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:23 pm

GRTS

Gritstone bio has been awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candidate for COVID-19. The contract is valued at up to $433 million, which has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:22 pm

MSOS

Cesar Reynoso of MGO suggests that despite the absence of the SAFER Banking Act and rescheduling, some operators in the cannabis industry will still perform well due to sustained demand. The article was published on Benzinga.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:20 pm

NLS

Nautilus, Inc. (NYSE:NLS) has received a notice of non-compliance from the New York Stock Exchange (NYSE) due to its average closing price being less than $1.00 per share over a consecutive 30 trading-day period. The company has six months to regain compliance with the minimum share price requirement. The notice does not affect the company's business, operations, or reporting requirements with the Securities and Exchange Commission.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:16 pm

GRWG

MSOS

GrowGeneration Co-Founder and CEO, Darren Lampert, spoke at the Benzinga Cannabis Capital Conference, emphasizing the company's careful approach to understanding the rules and regulations of every state they operate in.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:15 pm

MSOS

BeLeaf Medical CEO Jason Nelson spoke at the Benzinga Cannabis Capital Conference, discussing the changing nature of local regulatory functions in the cannabis industry.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:14 pm

FREQ

Frequency Therapeutics has terminated its sales agreement with Oppenheimer, effective immediately, according to an SEC filing. The termination is not subject to any penalties.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:12 pm

LDOS

Leidos (NYSE:LDOS) has announced a collaboration with Sofia Airport in Bulgaria to upgrade its hold baggage screening systems. The upgrades are designed to comply with the latest European regulations and will include three EU Standard 3 certified MV:3D Explosive Detection Systems and two new transmission X-ray systems. Leidos will also provide a 10-year service contract for the systems. The installation is expected to be completed in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:11 pm